US FDA grants fast track status for Pfizer-BioNTech's combination vaccine
The US FDA has granted Fast Track designation for Pfizer and BioNTech’s combination vaccine candidate against Covid-19 and influenza.
Source: pharmaceutical-technology.com
Stay updated with breaking news from Comirnaty Original. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The US FDA has granted Fast Track designation for Pfizer and BioNTech’s combination vaccine candidate against Covid-19 and influenza.
Health Canada has approved Pfizer Canada and BioNTech’s Comirnaty as a 30μg booster shot for 12 years and above aged individuals.